AEterna Zentaris Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (20)

Latest Posts

About This Stock More About This Stock
5 Tiny Biotech Stocks With Superb Growth Potential
Article By: Swarup Gupta
Wednesday, February 13, 2019 11:40 AM EST
After a disastrous end to 2018, pharma stocks have started the New Year on a considerably strong note. Here are several biotech stocks which would be a smart choice to invest in.
In this article: BDSI, CYTK, CLDX, ADRO, AEZS Also: XBI, BMY, CELG, LLY, LOXO
Read
Aeterna Zentaris Climbs On Phase 3 Announcement
Article By: Terry Chrisomalis
Sunday, April 30, 2017 3:48 AM EST
If Aeterna Zentaris posts positive results on Monday, the stock will soar much higher. Of course as with anything in biotech, there is some risk involved. The results could possibly end up being mixed or even worse, fail altogether.
In this article: AEZS Also: KERX
Read
Wall Street's Week Ahead: Aeterna Zentaris, Micron Technology And BlackBerry Ltd.
Article By: TipRanks
Sunday, March 27, 2016 2:39 PM EST
While new market expansion and acquisitions are expected to play out well, differing revenue structures and supply/demand concerns could unfavorably affect earnings. Here’s what to watch for from Aeterna Zentaris, Micron Technology, and BlackBerry.
In this article: AEZS, MU, BBRY (NOW BB)
Read
Week In Review: WuXi PharmaTech To List Subsidiary On China's Third Board
Article By: ChinaBio® Today
Tuesday, December 9, 2014 5:45 PM EST
China's largest CRO/CMO, has filed to list its chemical manufacturing subsidiary, SynTheAll Pharmaceutical Co. Ltd., on China's Third Board, a two-year old electronic OTC exchange. Shanghai Fosun Pharma will acquire a 65% sake in Suzhou Erye Pharma and more.
In this article: WX, ORMP, AEZS
Read
AEZS Adds Hollings Cancer Center To Multi-National Phase 3 Trial; MRNA And Mirna Amend License Agreement
Article By: BioMedReports
Friday, November 21, 2014 3:18 AM EST
AEZS announced the opening of a new clinical site at the Hollings Cancer Center of the Medical University of South Carolina. MRNA announced they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics.
In this article: AEZS, MRNA
Read

PARTNER HEADLINES

Latest Tweets for $AEZS

No tweets yet!